Practice of сlinical use of L-ornithine-L-aspartate to treat non-alcoholic fatty liver disease

Abstract

Nowadays, non-alcoholic fatty liver disease is the most common chronic hepatic disease in the world. NAFLD is a rapidly progressive disease among the Western population with no approved successful pharmacological therapy. Therefore, the aim of this study was to investigate whether the use of the Ukrainian product Gepatox is efficient within the complex therapy to treat NAFLD among the patients with diabetes mellitus. The study included 40 patients with 2 type diabetes mellitus having NAFLD in past medical history. As the result, it was found out that use of Gepatox within complex therapy to treat NAFLD, in the daily dose of 10 g (2 ampoules) for 10 days, helped reduce bilirubin in blood by 22%, ALT — by 62%, C-reactive protein — by 46%, cholesterol — by 21%, blood glucose — by 36% from the basic values.